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OBJECTIVE — This study examined the effectiveness of the German diabetes disease man-
agement program (DMP) for patients with varying numbers of other medical conditions with
respect to their health-related quality of life (HRQoL).
RESEARCH DESIGN AND METHODS — A questionnaire, including the HRQoL-
measuredEQ-5D,wasmailedtoarandomsampleof3,546patientswithtype2diabetes(59.3%
female). The EQ-5D score was analyzed by grouping patients according to those on a DMP and
those receiving routine care.
RESULTS — The analysis showed that participation in the DMP (P  0.001), the number of
other medical conditions (P  0.001), and the interaction between the DMP and the number of
other conditions (P  0.05) had a signiﬁcant impact on the EQ-5D score.
CONCLUSIONS — Our ﬁndings suggest that the number of other medical conditions may
have a negative impact on the HRQoL of patients with type 2 diabetes. The results demonstrate
that the German DMP for type 2 diabetes may help counterbalance this effect.
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P
revious research showed that the
presence of other medical condi-
tions had a negative impact on
health-related quality of life (HRQoL) for
patients with type 2 diabetes (1–3). In
Germany, a special disease management
program (DMP) has been in place
throughout the country since 2003, aim-
ing to better structure and coordinate the
care of patients with type 2 diabetes. This
primary care–based continuous program
comprises elements of the Chronic Care
Model and is accessible for all patients
with type 2 diabetes (4,5). This study
aimed to examine the effectiveness of the
German diabetes DMP for patients with
varying numbers of other medical condi-
tions with respect to their HRQoL.
RESEARCH DESIGN AND
METHODS— This study was inte-
gratedintotheEvaluationofaLarge-Scale
Implementation of Disease (ELSID) study
(2005–2007), a comparative evaluation
oftheGermanDMPforpatientswithtype
2 diabetes. This controlled observational
studyaimstocomparetheeffectivenessof
care provided by the DMP with that of
routine care. A total of 20,625 patients
were included, of whom 59.2% were fe-
male. The sample and the classiﬁcation of
patients in terms of enrollment in a DMP
were based on routine claims data (6).
The basis for the survey study presented
in this article was a random sample of
3,546patients(59.3%female)takenfrom
the ELSID population. In 2006, these pa-
tients received questionnaires with a
cover letter sent by their health insurance
provider. Details of the data acquisition
have been published (5).
We used the EQ-5D, a validated ge-
neric instrument for measuring HRQoL
that is available in more than 50 lan-
guages.TheEQ-5Dscorerangesfrom0to
1 and can be calculated by applying
scores from the EQ-5D preference
weights elicited from the general popula-
tion. For this study, the EQ-5D score was
calculated using the value set for the Eu-
ropean population (7,8). Further investi-
gations have demonstrated the usefulness
of the EQ-5D in identifying determinants
of health states (9,10). The minimal im-
portantdifferencefortheEQ-5Dhasbeen
reported in the relevant literature as a
change in score of at least 0.05 points
(11).
The questionnaire is comprised of
questions on sociodemographic charac-
teristics (age, sex, educational level, mar-
ital status, and household income), self-
reported health information (weight,
height, and smoking status), and a list of
conditions other than type 2 diabetes in
lay terms (hypertension, osteoarthrosis,
cancer, previous stroke, coronary heart
disease, chronic obstructive pulmonary
disease, asthma, heart failure, previous
heart attack, and other). Study protocols
oftheELSIDstudyandofthissurveywere
both approved by the ethics committee of
the University of Heidelberg.
Statistical analysis
All analyses were conducted with SPSS
software (version 15.0; SPSS, Chicago,
IL). The EQ-5D score was analyzed by
grouping patients according to those who
participate in the German diabetes DMP
and patients in routine care. To compare
the EQ-5D score in both groups, we per-
formedANCOVAwiththeDMP(yes/no),
the number of other medical conditions
(0–6 and more), and sex as independent
factors and age as a covariate. We consid-
ered all main effects and the interaction
effectoftheDMPandthenumberofother
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P  0.05.
RESULTS— Of the 3,546 question-
naires mailed, 1,532 were returned (re-
sponse rate 42.2%). Valid data were
available for 1,399 patients. The EQ-5D
score could be calculated for 1,291 pa-
tients. A nonresponder analysis (on the
basis of claims data) showed that respond-
ers, compared with nonresponders, were
younger, a higher proportion were female,
and more patients were participating in
a DMP.
Patient characteristics
Of the 1,399 patients included, 649 were
male (46.4%) and 750 were female
(53.6%).Themeanagefortheentiresam-
ple was 70.3  8.5 years. On average, the
patients were enrolled for 26.8  9.0
months in the DMP for type 2 diabetes.
Signiﬁcant differences between the two
patient groups did not exist for the whole
sample but did for some subgroups: pa-
tients with no other conditions (age), one
other condition (coronary heart disease
and cancer), two other conditions (previ-
ous heart attack), three other conditions
(education), ﬁve other conditions (osteo-
arthrosis), and six other conditions (heart
failure).
The analysis for the number of other
medical conditions revealed that 92.8%
of the DMP patients and 93.4% of the pa-
tients in routine care had one or more
other conditions. It also showed that
70.7% of patients who were enrolled in
the DMP and 72.9% of patients who were
not enrolled had two or more conditions.
Moreover, 25.2% of patients in the DMP
group and 28.5% in the non-DMP group
had four or more other conditions.
EQ-5D score
The analysis of the main effects showed
thatparticipationintheDMP[F(1, 1,276)
11.50; P  0.001], the number of other
conditions [F(6, 1,276) 44.35; P0.001],
sex[F(1, 1,276)19.22;P0.001],andage
[F(1, 1,276)  14.89; P  0.001] had a sig-
niﬁcant impact on the EQ-5D score. The
analysis of the interaction effect (between
DMP and the number of other conditions)
also revealed a signiﬁcant impact on the
EQ-5D score [F(6, 1,276)  2.19; P  0.05].
An assessment of the estimated
EQ-5D score mean values showed that as
the number of other conditions rose, the
score decreased in both groups. Starting
at 0.826 (95% CI 0.773–0.879) for DMP
patientsand0.790(0.719–0.862)forpa-
tients in routine care with no other con-
ditions, the EQ-5D score decreased for
patientswithsixormoreotherconditions
to 0.539 (0.487–0.590) in the DMP
group and to 0.398 (0.338–0.457) for
patients in routine care. With the excep-
tionofpatientswithtwootherconditions,
patients in the DMP have higher esti-
mated mean values for all numbers of
other conditions. A minimal important
difference between DMP and routine care
existedforpatientswithfourothercondi-
tions (DMP  0.627; routine care 
0.566), ﬁve other conditions (DMP 
0.575; routine care  0.510), and six or
more other conditions (DMP  0.539;
routine care  0.398) (Table 1).
CONCLUSIONS— The results of
our study demonstrate that participation
in a DMP may have a greater impact on
HRQoL for patients with type 2 diabetes,
especially for those with increasing num-
bers of comorbid conditions. We were
able to show that HRQoL decreased con-
tinuously and the difference between the
DMPandroutinecareclearlyincreasedas
the number of other medical conditions
rose. The study thus provides additional
research evidence on the positive impact
of the German DMP, which is in line with
previousstudies(6,12).Inaddition,these
results may suggest that the number of
other medical conditions has an impor-
tant inﬂuence on HRQoL.
The higher HRQoL in patients with
type 2 diabetes with comorbidity in the
DMP group may be related to different
factors. According to previous studies,
structured chronic care may improve
medical care for other conditions as well
(13,14). This may be a result of both
greater motivation on the part of the doc-
tor to provide treatment and more oppor-
tunitiestodoso,asthesepatientsvisitthe
practice regularly. The ﬁnding may also
reﬂect the added value of primary care, as
this is by deﬁnition highly accessible, pa-
tient-oriented, and comprehensive (15).
This study has some limitations.
Because the DMP was established nation-
wide before our study began, ran-
domization was not possible. Further-
more, we do not know whether and how
motivation to enroll in the DMP affects
HRQoL, and differences (i.e., age, sex,
and DMP status) between responders and
nonresponders may also affect our
results.
However, our ﬁndings suggest that
having additional medical conditions
may have a negative impact on the
HRQoL of patients with type 2 diabetes.
Our results demonstrate that primary
care–based structured and coordinated
care, such as that offered in the German
DMP for type 2 diabetes, may help coun-
terbalance this effect.
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Table1—ComparisonofEQ-5Dscorebetweentype2diabetespatientsindiseasemanagement
and patients in routine care (N  1,291)
Other
conditions
Routine care Disease management
n Mean  SEM 95% CI n Mean  SEM 95% CI
0 40 0.790  0.036 0.719–0.862 66 0.826  0.027 0.773  0.879
1 111 0.775  0.021 0.734–0.816 189 0.789  0.015 0.759  0.819
2 140 0.682  0.018 0.646–0.717 214 0.670  0.014 0.642  0.699
3 91 0.642  0.023 0.598–0.687 178 0.654  0.016 0.622  0.686
4 64 0.566  0.027 0.513–0.619 93 0.627  0.022 0.584  0.671
5 42 0.510  0.034 0.443–0.578 60 0.575  0.027 0.522  0.628
6  46 0.398  0.030 0.338–0.457 65 0.539  0.026 0.487  0.590
Data are means  SEM.
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